Health Canada grants market authorisation to Rozlytrek (entrectinib) for ROS1-positive, locally advanced or metastatic non-small cell lung cancer patients, not previously treated with crizotinib

20 May 2020 - Data show responses in 73% of patients who were treated with Rozlytrek. ...

Read more →

AbbVie receives Health Canada approval for the combination of Venclexta (venetoclax) with obinutuzumab for patients with previously untreated chronic lymphocytic leukaemia

5 May 2020 - Venclexta (venetoclax) plus obinutuzumab is the first chemotherapy-free, fixed-duration combination regimen approved by Health Canada for patients ...

Read more →

Health Canada approves Rozlytrek (entrectinib) for NTRK gene fusion-positive solid tumours in locally advanced or metastatic patients

28 April 2020 - Data show more than half of trial patients across all 10 tumour types studied had responses to ...

Read more →

Health Canada approves an extended indication for Kisqali (ribociclib) in combination treatment

16 April 2020 - Breast cancer is the most common female cancer in Canada. ...

Read more →

Advanced Accelerator Applications announces Health Canada approval of Netspot diagnostic imaging agent kit to detect neuroendocrine tumours

7 April 2020 - Netspot is the first and only kit for the preparation of gallium (68 Ga) oxodotreotide injection for ...

Read more →

'It's outrageous': costly cancer drugs thrown out because of one-size-fits-all packaging

1 March 2020 - Prescription drug negotiations steeped in secrecy, leaving taxpayers in the dark on costs. ...

Read more →

Janssen receives Health Canada approval of Balversa (erdafitinib), the first FGFR kinase inhibitor for the treatment of patients with locally advanced or metastatic urothelial carcinoma with certain FGFR genetic alterations

24 February 2020 - Diagnostic testing is available to identify which patients are most likely to benefit from BALVERSA, offering a ...

Read more →

Health Canada approves Keytruda (pembrolizumab) as first-line treatment for patients with advanced renal cell carcinoma

23 January 2020 - Approval based on results of KEYNOTE-426, Where Keytruda in combination with axitinib reduced the risk of death ...

Read more →

Health Canada approves Astellas' Xospata (gilteritinib) for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation

14 January 2020 - Xospata is the first and only targeted treatment approved by Health Canada for patients with relapsed or ...

Read more →

New treatment approved in Canada for most common type of leukaemia

8 January 2020 - Calquence (acalabrutinib) is now available for adult patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. ...

Read more →

Health Canada approves new indication for Erleada (apalutamide) for the treatment of metastatic castration-sensitive prostate cancer

16 December 2019 - Janssen announced today that Health Canada, following a priority review, has approved Erleada (apalutamide) for the ...

Read more →

Novartis completes certification of initial sites in Ontario for first approved Canadian CAR-T therapy, Kymriah (tisagenlecleucel)

12 December 2019 - Ontario government to reimburse Kymriah therapy for certain patients with life-threatening cancers who are in critical need. ...

Read more →

International collaboration among Canadian, U.S. and Australian regulators leads to new options for the treatment of cancer

6 December 2019 - Health Canada also provides an update on approvals of new drugs and medical devices for Canadians. ...

Read more →

Seattle Genetics announces Health Canada approval of Adcetris (brentuximab vedotin) in combination with chemotherapy in frontline CD30-expressing peripheral T-cell lymphoma

25 November 2019 - Approval of supplemental new drug aubmission for Adcetris in combination with CHP chemotherapy in frontline CD30-expressing peripheral ...

Read more →

Health Canada approves Lonsurf (trifluridine/tipiracil) for adults with metastatic gastric cancer during stomach cancer awareness month

21 November 2019 - New indication improves overall survival for end stage metastatic disease ...

Read more →